Evidence suggests that there is a significant decrease in potential harm for those who switch to glo exclusively over the 6-month period. This is in comparison to continuing to smoke cigarettes.The scientific support for glo's potential to be a lower risk product is provided by the gold-standard i indicatorIndicator supports scientific support of glo's ability as a reduced-risk product. First long-term study to show sustained reductions in exposure to toxicants and indicators that could harm smokers who switch to glo.BAT supports the delivery of A Better TomorrowTM through reducing its global health impact by encouraging smokers to quit smoking and switch to lower risk alternatives.LONDON, 1 July 2021: A new study published in the journal Internal and Emergency Medicine today shows that switching to glo, the flagship Tobacco Heating Product (THP) by BAT, can dramatically reduce the amount of toxicants and other indicators of potential harm associated with several smoking-related diseases.These results were recorded at 6 months of a 12-month-long study and showed statistically significant differences across a range "biomarkers" of exposure (BoE**) and indicators of possible harm (BoPH**) compared to continuing to smoke.The biomarkers that were measured showed similar results for most participants who quit smoking.According to the toxicants tested, glo users had a:A biomarker that predicts lung cancer risk has seen a significant reductionA significant decrease in white blood cells count is a sign of cardiovascular disease risk (CVD), and other smoking-related diseases.Lower risk of CVD associated with an increase in HDL cholesterolTwo key indicators of lung health are improvingA key indicator of oxidative strain, which is implicated in many smoking-related diseases such as hypertension and CVD, has seen improvement.BAT's Director for Scientific Research, Dr David O'Reilly said that these are very exciting results because they enable us to see the potential risk reduction that switching to glo completely can bring. This study showed that switching to glo can lower smokers' exposure to toxicants. This reduces their likelihood of developing certain smoking-related diseases. * The study that showed a significant decrease in BOPH (some comparable to quitting completely) is encouraging. It also provides scientific support for the harm reduction potential and how it supports our aim to build A Better TomorrowTM through reducing our health impact.About the studyThe study included UK-based smokers between the ages of 23 and 55 who were in good health. They could choose to continue smoking cigarettes or switch to glo. Smokers who didn't intend to quit were randomly assigned to continue to smoke cigarettes or to use only glo. Smokers who wanted to quit received nicotine replacement therapy and access a cessation counselor. To act as a control, a group of "never smokers", who continued to not use tobacco or nicotine products, was also included.This study was intended to examine the risk reduction potential for glo when it is used in a real-world setting, rather than in a controlled environment. Only one intervention was required: monthly clinic visits where blood, urine, and other measurements were taken. These samples were tested for "biomarkers to exposure" (to certain cigarette smoke toxicants) as well as "biomarkers that could cause harm". To ensure compliance, the cessation and glo groups were also tested for CEVal, which indicated whether they had smoked cigarettes in the last 24 hours.The final results of the study will be available by the end 2021. They will show whether or not the exposure to toxicants and biomarkers that could cause harm has been maintained throughout the course of the study.###Notes for EditorsAbout the BATBAT, a multi-category, leading consumer goods company, was established in 1902. We aim to create a Better Tomorrow by decreasing the health impact of our businesses, which includes:A commitment to provide adult consumers with a wider range of fun and less risky productsIt is important to keep in mind that combustible cigarettes pose serious risks to your health.Encourage those who smoke to quit completely and switch to less-risk, scientifically-supported alternativesSharing and tracking our progress in transformationThe company announced that it will increase its non-combustible product consumer base to 50 million by 2030. It also plans to generate at least 5 billion dollars in New Categories revenue in 2025.* Based on the evidence and assuming a complete quit of cigarette smoking. These products can be addictive and they are not risk-free.**Biomarker of Exposure Associated Toxicant Carcinogen Respiratory Toxicant CV Toxicity Reproductive ToxicantNNN NNNY1-OHP Pyrenee YNNAL NNK Yo-Tol O-toluidine Y3-HPMA Acrolein A YHMPMA Crotonaldehyde4-ABP 4-aminobiphenyl (Y)eCO Carbon monoxide YHEMA Ethylene Oxide Y2-AN 2-aminonaphthalene (Y)MHBMA 1,3 Butadiene YS-PMA Benzene Y Y YCEMA Acrylonitrile Yellow YAssociation for Biomarker of Potential Harm IndiatorCVD HDL Lipid metabolismWBC General inflammation, COPD, and cancersFEV1 Lung disease Respiratory diseaseFeNO Bronchodilation/vascular Tone Respiratory disease, CVDsICAM Endothelial dysfunction CVD11-dTx B2 Platelet activation/coagulation CVD8-epi-8F2a Oxidative Stress CVD, COPD and CancersExposure to NNAL NNK Lung cancerForward-Looking StatementsReferring to "BAT", "BAT Group", "we", "us", and "our" refers to BAT Group operating businesses, individually or collectively. This release contains forward-looking statements. These statements include statements that are within the scope of the US Private Securities Litigation Reform Act (1996). These statements can be made using words and phrases such as "believe", "anticipate,"" "could", "may,"," would,"," should,","would,","should,","intend,","plan,","potential,","predict,","estimate,"project," position," strategy, "outlook", target, and similar expressions. These statements include statements about our current beliefs and intentions. They also reflect the knowledge and information that we have at the time of preparation.Forward-looking statements include assumptions and estimates that are subjected to uncertainties, risks and other factors. Although the expectations expressed in this release seem reasonable, they could be affected by many variables that could cause actual results not to match those anticipated.There are many factors that could lead to actual results being different from the ones projected in forward-looking statements. These include the effects of adverse legislation or regulation, the inability of BAT to develop, market and deliver its New Categories strategy, the impact on tobacco, nicotine, and New Categories-related taxes, changes in domestic and international economic and political conditions, and the impact of serious injury or death at work. Forward-looking statements are based on current knowledge at the time of preparation. BAT does not assume any obligation to revise or update these forward-looking statement, regardless of whether new information or future events occur. These forward-looking statements should not be relied upon by readers.This release contains information that is intended to provide information about BAT only to stakeholders. It is not intended for general consumption. BAT, its officers, directors, employees, agents, advisers, and employees do not accept responsibility for any other person to whom the material may be shown. Any such responsibility or liability is explicitly disclaimed by BAT. This release does not contain any product marketing, promotion or advertising material. This material should not be considered an offer to purchase or solicitation to buy any of our products. Only the laws in the jurisdictions where our products are sold are applicable to them.British American Tobacco, p.l.c. provides additional information about these and other factors. The filings of British American Tobacco p.l.c. with the US Securities and Exchange Commission ("SEC") include the Annual Report on form 20-F and Current Reports forms 6-K. These documents can be accessed free of charge on the SEC's website at http://www.sec.gov. sec. sec.iUS Institute of Medicine: Scientific Standards For Studies on Modified Risk Tobacco Products 2012.
